Mentis Cura is committed to delivering early, accurate and affordable diagnostics for dementia and other brain disorders backed by robust clinical trials.
Learn moreMentis Cura and Japanese Nihon Medi-Physics met in Oslo last on 24th January to celebrate their exclusive partnership agreement, signed in Tokyo in December 2018.
Various stakeholders celebrated this milestone with us, including Norway Health Tech, who gives an excellent account of the event on their website (link to full article below): “Norway Health Tech is applauding our member Mentis Cura for exceptional good work. We are happy to witness such a good success story of hard work and admirable results. This is well deserved. May 2019 bring both positive numbers and better quality of life for people with dementia.”
Read Norway Health Tech’s full article here: “Bringing Norwegian-Icelandic dementia diagnostics to the Japanese healthcare market”.
Mentis Cura and Nihon Medi-Physics enter into an exclusive agreement to accelerate clinical development of Mentis Cura software as dementia diagnosis EEG biomarker in Japan.
Mentis Cura AS and Nihon Medi-Physics (NMP) today announced the signing of an exclusive partnership agreement for the development, commercialization and sales of EEG analysis software for the Japanese market. In the agreement Mentis Cura will be responsible for clinical development and regulatory clearance for the EEG analysis software, and NMP will be responsible for its exclusive commercialization in Japan.
Press release
Utilizing a simple 5-minute recording of brain activity, Mentis Cura's technology can pick up specific fingerprints of diseases. The foundation for this unique capability is the company's database of 3000+ patients followed for up to 10 years.
Learn more
Based on more than a decade of clinical research, Mentis Cura offers an important input for doctors to support their differential diagnosis of dementia, which helps avoid harmful side effects.
Building on the success of Sigla, we are now developing a new product that supports doctors in making a prognosis for those experiencing early symptoms of cognitive impairment.
On the basis of extensive clinical studies and a strong knowledge base we are working closely with stakeholders to develop solutions that can support diagnosis.
Personalized medicine approaches have been highly successful in Oncology and pharmaceutical companies are increasingly applying the same concepts in CNS projects. Our technology can support clinical trials in several ways ranging from patient selection to early signs of efficacy.